Company |
Location |
Amt. (M) |
Details |
Date |
TOTAL: $827.85M | ||||
Akeso Biopharma Inc. |
Zhongshan, Guangdong Province, China |
$20 |
Akeso raised $20M in a series A round funded by local investors |
12/9/15 |
Allena Pharmaceuticals Inc. |
Newton, Mass. |
$53 |
Allena completed a $53M series C financing led by Partner Fund Management and included additional new investors Fidelity Management & Research Co. and Wellington Management Co., and existing investors Frazier Healthcare, HBM Biocapital and Pharmstandard International SA |
12/10/15 |
Aquinnah Pharmaceuticals Inc. |
Cambridge, Mass. |
$5 |
Aquinnah received a $5M investment from Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, in a private equity financing |
12/22/15 |
Ascletis Pharmaceuticals Co. Ltd. |
Hangzhou, China |
$20 |
Ascletis received $20M from an investment by Goldman Sachs |
12/3/15 |
Aslan Pharmaceuticals Pte Ltd. |
Singapore |
$34 |
Aslan raised $34M in series C funding led by Accuron Technologies; other new investors include Tianda Pharmaceuticals and Haitong International, and they were joined by existing investors Morningside, Bioveda, Cenova and Sagamore Bioventures |
12/8/15 |
Clearside Biomedical Inc. |
Alpharetta, Ga. |
$20 |
Raised $20M in a series C financing from new investors Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management, along with existing investors |
12/4/15 |
Constellation Pharmaceuticals Inc. |
Cambridge, Mass. |
$55 |
Constellation completed a $55M mezzanine round of financing co-led by Topspin Partners and including new money from several other investment funds; existing investors Third Rock Ventures, The Column Group, Venrock and SR One also participated |
12/10/15 |
Effector Therapeutics Inc. |
San Diego |
$40 |
Effector raised $40M in a series B round from new investors Altitude Life Science Ventures, Abbvie Biotech Ventures and Biomed Ventures; existing investors – Abingworth, Novartis Venture Fund, SR One, The Column Group, U.S. Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital also participated |
12/23/15 |
Enlibrium Inc. |
San Diego |
$15 |
Enlibrium raised $15M in a series A financing co-led by Avalon Ventures and TPG Biotech, with participation from Correlation Ventures and Osage University Partners |
12/7/15 |
Gamamabs Pharma SA |
Paris |
$15.9 |
Gamamabs completed a €15M (US$15.9M) series B financing led by Biodiscovery 4; Innobio, Irdinov, Alto Invest and Ixo Private Equity also subscribed to the round |
12/16/15 |
Gelesis Inc. |
Boston |
$31.5 |
Gelesis raised $31.5M in a round that included Cormorant Asset Management and additional undisclosed new institutional investors along with current investors Invesco Asset Management, Puretech and the Priztker/Vlock Family Office |
12/21/15 |
Hallux Inc. |
Laguna Hills, Calif. |
$7.1 |
Hallux completed a series A round of $7.1M led by Deerfield Management |
12/17/15 |
IBD |
Montreal |
$14.1 |
Raised $14.1M in series A round, and could get up to $40M more from Celgene Corp.; Versant Ventures led the round, with participation from Inserm Transfert Initiative and Fonds de Solidarité FTQ |
12/11/15 |
Immunome Inc. |
Philadelphia |
$5 |
Immunome raised $5M in a series A preferred stock financing, with $3.6M funded and $1.4M committed and expected to close in the near future; Broadband Capital Management acted as exclusive placement agent |
12/22/15 |
Inthera Bioscience |
Zurich, Switzerland |
$3.75 |
Inthera Bioscience closed a €3.4M (US$3.75M) financing round led by MS Ventures, with equal contribution from Aglaia Oncology Fund II and Novo Seeds; EVA Basel also participated |
12/15/15 |
Kahr Medical Ltd. |
Jerusalem |
$12 |
Kahr Medical raised $12M at the first closing of a $15M series B financing; the second closing, for the additional $3M, is expected to occur by Feb. 15, 2016; Korea Investment Partners, Mirae Asset Venture Investment and DSC Investment participated in the first closing, along with existing investor Flerie Invest AB |
12/16/15 |
Kallyope Inc. |
New York |
$44 |
Raised $44M in a series A financing |
12/11/15 |
Kesios Therapeutics Ltd. |
London |
$29 |
Kesios raised £19M (US$28.5M) in a series A round from Imperial Innovations Group plc, which is following on after supplying the seed funding for Kesios, along with SV Life Sciences and Abingworth |
12/2/15 |
Kyras Therapeutics Inc. |
New York |
ND |
Investors included Versant Ventures |
12/11/15 |
Navitor Pharmaceuticals Inc. |
Cambridge, Mass. |
$33 |
Navitor raised $33M in a series B round led by Brace Pharma Capital, and including new investors Remeditex Ventures, Sanofi-Genzyme Bioventures and individual investors, as well as existing investors Polaris Partners, Atlas Venture, Johnson & Johnson Innovation and Glaxosmithkline plc's SR One Ltd. |
12/18/15 |
Nemocure Medical Innovations Inc. |
Worcester, Mass. |
ND |
Nemocure closed a series A round |
12/8/15 |
Neurona Therapeutics Inc. |
South San Francisco |
$23.5 |
Neurona raised $23.5M in a series A round led by The Column Group |
12/2/15 |
Nohla Therapeutics Inc. |
Seattle |
$21 |
Closed an oversubscribed first capital raising of $21M from several institutional investors |
12/28/15 |
ORIC Pharmaceuticals Inc. |
South San Francisco |
$53 |
ORIC raised $53M in a series B round from The Column Group, Kravis Investment Partners, Topspin Partners, Orbimed Advisors, Ecor1 and Foresite Capital |
12/3/15 |
Orig3n Inc. |
Boston |
$12.5 |
Orig3n raised $12.5M from a series A round co-led by Hatteras Venture Partners and Syno Capital; also participating was new investor Defta Partners and existing investors Harris & Harris Group Inc., Labcorp, MGC Venture Partners and KTB-KORUS Fund |
12/17/15 |
Orthosera Dental (subsidiary of Orthosera GmbH; formerly Lacerta Technologies) |
Krems an der Donau, Austria |
ND |
Orthosera Dental closed its first institutional investment round led by Euroventures and joined by Hungarian and U.S. business angels |
12/16/15 |
Poseida Therapeutics Inc. |
La Jolla, Calif. |
$30 |
Poseida raised $30M in a series A round from lead investor Malin Corp. plc |
12/17/15 |
Prosetta Biosciences Inc. |
San Francisco |
$31 |
Raised about $31M in a series D private placement; investors included Alger Management and Takeda Pharmaceutical Co. Ltd. |
12/4/15 |
Qu Biologics Inc. |
Vancouver, British Columbia |
$2.5 |
Qu Biologics closed a private financing of C$3.5M (US$2.5M) |
12/24/15 |
Remedy Pharmaceuticals Inc. |
New York |
$9 |
Remedy completed a $9M financing led by Vertical GP-5 LLC, an affiliate of The Vertical Group, and other new investors with participation from existing investors |
12/2/15 |
Rubius Therapeutics Inc. |
Cambridge, Mass. |
$25 |
Rubius launched with an initial capital commitment of $25M from Flagship Ventures |
12/10/15 |
Sino Health (part of Sinopharm Group Co. Ltd.; Beijing) |
Beijing |
ND |
Frontline Bioventures led a series A round for Sino Health, an invested company of Sinopharm |
12/7/15 |
Symic Biomedical Inc. |
San Francisco |
$25 |
Symic raised $25M in a series A-2 financing led by Lilly Ventures and included participation by its existing major investors and undisclosed new investors; the company raised $15M in a series A round earlier this year |
12/2/15 |
Tianjin Cansino Inc. |
Shanghai |
$30 |
Tianjin Cansino received a $30M investment from Qiming Venture Partners and Lilly Asia Ventures |
11/4/15 |
True North Therapeutics Inc. |
South San Francisco |
$40 |
Raised $40M in series C equity funding led by New Leaf Venture Partners, with participations from new investors Perceptive Advisors and Cowen Private Investments, as well as existing investors Kleiner Perkins Caufield & Byers, MPM Capital, Orbimed, SR One and Baxalta Ventures |
12/4/15 |
Velicept Therapeutics Inc. |
Malvern, Pa. |
$21 |
Velicept raised $21M in a series B round led by CAM Capital and Longitude Capital |
12/18/15 |
X4 Pharmaceuticals Inc. |
Cambridge, Mass. |
$37.5 |
X4 raised $37.5M in a series A round (completed in late August, according to an SEC filing) with Maxim Merchant Capital as the sole placement agent and Cormorant Asset Management serving as lead investor |
12/14/15 |
Zavante Therapeutics Inc. |
San Diego |
$10 |
Zavante raised $10M in its initial round |
12/17/15 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||